美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

SeaStar Medical Holding Corporation

0.0281

0.0000

成交量：121.00

成交额：3.02

市值：78.44万

市盈率：-0.02

高：0.0281

开：0.0281

低：0.0281

收：0.0281

52周最高：0.0549

52周最低：0.0084

股本：2,791.46万

流通股本：2,791.46万

量比：0.08

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-1.6425

净资产收益率：-290.37%

总资产收益率：-86.54%

市净率：0.07

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

SeaStar Medical Holding Corporation

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.seastarmedical.com

邮编：

- -

电话：

- -

传真：

- -

简介：

SeaStar Medical Holding Corp最初于2007年6月6日以Nephrion，Inc.的名义在特拉华州注册成立。2007年8月3日，公司更名为CytoPherx公司。2019年6月19日，在一项合并交易中，CytoPherx公司更名为SeaStar Medical公司，SeaStar Medical公司是一家医疗技术公司，主要专注于开发和商业化其主要候选产品，选择性细胞异位装置（“SCD”），用于儿童和成人急性肾损伤（“AKI”）适应症。SeaStar Medical目前正在完成一项关于SCD的人道主义设备豁免（“HDE”）的提交，用于治疗持续肾替代疗法（“CRRT”）的儿童AKI患者，并完成一项针对CRRT成人AKI患者的关键试验的设计。SCD于2022年4月29日获得美国食品和药物管理局（“FDA”）的突破性设备指定，用于治疗18岁及以上AKI成人患者的免疫调节失调。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ICUCW/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ICUCW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","market":"US","secType":"STK","nameCN":"SeaStar Medical Holding Corporation","latestPrice":0.0281,"timestamp":1774618828143,"preClose":0.0281,"halted":0,"volume":121,"delay":0,"changeRate":0,"floatShares":27914598,"shares":27914598,"eps":-1.6425,"marketStatus":"交易中","change":0,"latestTime":"03-27 09:40:46 EDT","open":0.0281,"high":0.0281,"low":0.0281,"amount":3.02137,"amplitude":0,"askPrice":0.025,"askSize":1,"bidPrice":0.0249,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.6425,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0281,"postHourTrading":{"tag":"盘后","latestPrice":0.0271,"preClose":0.028,"latestTime":"16:34 EDT","volume":552,"amount":14.959462,"timestamp":1774557247297,"change":-0.0009,"changeRate":-0.032143,"amplitude":0.032143},"volumeRatio":0.080304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","floatShares":27914598,"roa":"-86.54%","roe":"-290.37%","lyrEps":0,"volumeRatio":0.080304,"shares":27914598,"dividePrice":0,"high":0.0281,"amplitude":0,"preClose":0.0281,"low":0.0281,"week52Low":0.0084,"pbRate":"0.07","psRate":"0.89","week52High":0.0549,"institutionHeld":0,"latestPrice":0.0281,"eps":-1.6425,"divideRate":0,"volume":121,"delay":0,"ttmEps":-1.6425,"open":0.0281,"prevYearClose":0.0113,"prevWeekClose":0.0261,"prevMonthClose":0.0299,"prevQuarterClose":0.0113,"fiveDayClose":0.0261,"twentyDayClose":0.0299,"sixtyDayClose":0.011},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ICUCW\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"ICUCW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盘后","dateTimestamp":1774411200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ICUCW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ICUCW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.seastarmedical.com","stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":0.2391},{"period":"3month","weight":1.4779},{"period":"6month","weight":-0.1139},{"period":"1year","weight":-0.3622},{"period":"ytd","weight":1.4779}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"SeaStar Medical Holding Corp最初于2007年6月6日以Nephrion，Inc.的名义在特拉华州注册成立。2007年8月3日，公司更名为CytoPherx公司。2019年6月19日，在一项合并交易中，CytoPherx公司更名为SeaStar Medical公司，SeaStar Medical公司是一家医疗技术公司，主要专注于开发和商业化其主要候选产品，选择性细胞异位装置（“SCD”），用于儿童和成人急性肾损伤（“AKI”）适应症。SeaStar Medical目前正在完成一项关于SCD的人道主义设备豁免（“HDE”）的提交，用于治疗持续肾替代疗法（“CRRT”）的儿童AKI患者，并完成一项针对CRRT成人AKI患者的关键试验的设计。SCD于2022年4月29日获得美国食品和药物管理局（“FDA”）的突破性设备指定，用于治疗18岁及以上AKI成人患者的免疫调节失调。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.807433},{"month":2,"riseRate":0.6,"avgChangeRate":0.046821},{"month":3,"riseRate":0.6,"avgChangeRate":-0.029379},{"month":4,"riseRate":0.2,"avgChangeRate":-0.175752},{"month":5,"riseRate":0,"avgChangeRate":-0.169816},{"month":6,"riseRate":0.4,"avgChangeRate":-0.081355},{"month":7,"riseRate":0.6,"avgChangeRate":0.163583},{"month":8,"riseRate":0.2,"avgChangeRate":-0.152907},{"month":9,"riseRate":0.4,"avgChangeRate":-0.100305},{"month":10,"riseRate":0.8,"avgChangeRate":0.602108},{"month":11,"riseRate":0.4,"avgChangeRate":-0.176512},{"month":12,"riseRate":0,"avgChangeRate":-0.181163}],"exchange":"NASDAQ","name":"SeaStar Medical Holding Corporation","nameEN":"SeaStar Medical Holding Corporation"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ICUCW\",market:\"US\",,,undefined,":null}}